Fabrice Viviani

TL;DR: These studies identify tapinarof as an AhR agonist and confirm that its efficacy is dependent on AhR.

TL;DR: A progressive series of assays are described to demonstrate the potential clinical value of a novel RORγ inverse agonist small molecule with high potency and selectivity, which will enter clinical trials in late 2015 for psoriasis patients.

TL;DR: A novel class of DGAT1 inhibitors containing a thiadiazole core has been discovered that show in vivo activity in target tissues and an appropriate ADME profile.

TL;DR: In this article, the novel materials of formula (I) were introduced, where an optionally substituted L-aryl or L-hetero-aryl, such that L is a single bond, alkyl, CO, or CO-alk, or L -X, with X being O or S; R2 is H or alkyls; R3 is an alkyll optionally substituted by Hal; and R4 is Hou Hal, wherein said materials are in any isomeric form and the salts thereof, to be used as drugs.

TL;DR: Chemical modulation of a formerly disclosed DGAT-1 inhibitor resulted in the identification of a compound with a suitable profile for preclinical development and optimisation of solubility is discussed and a PK/PD study is presented.